(MT Newswires) -- Bristol-Myers (BMY) CEO Christopher Boerner discusses the company's transition, marked by a series of transactions and the development of new drugs, particularly in neuroscience and oncology. He talks about growth prospects, the pipeline of 16 new drugs in development between now and the end of the decade, and the return of capital to shareholders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.85 USD | +0.34% | -8.34% | -12.59% |
Apr. 26 | S&P 500 Q1 earnings estimated growth improves; stocks up for week | RE |
Apr. 26 | Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.59% | 90.92B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology